Gravity-Powered Biomedical Device Paves Way for Low Cost POC Diagnostic Testing
|
By LabMedica International staff writers Posted on 14 Jul 2023 |

The need for simple, user-friendly, point-of-care devices continues to exist. Many prototype and market-ready devices aim to simplify diagnosis and crucial biomarker measurement processes using minimal liquid samples, power, and professional knowledge. These innovations aim to enhance healthcare delivery for the vast population residing in low-resource locales, far from well-equipped hospitals and qualified medical personnel. These tests generally share certain prerequisites: they need to transport, combine, and assess minute biological sample-containing droplets and their active ingredients, enabling specific biomarker measurements. High-end devices employ miniature electric pumps to facilitate these reactions, while others leverage the dynamics of liquids within microchannels, or microfluidics, to produce a suction-like effect. Each method comes with its own distinct benefits and challenges. Now, researchers have demonstrated a first-of-its-kind approach that only uses gravity to power point-of-care biomedical devices and also offers certain advantages over currently existing platforms.
Biomedical engineers at Duke University (Durham, NC, USA) have devised a completely new approach for building point-of-care diagnostic tools, which only leverages gravity to transport, mix, and manipulate the liquid droplets involved. This proof-of-concept uses readily available materials and minimal power to interpret results, making it a potentially beneficial option for use in settings with limited resources. The innovative gravity-based technique is based on a selection of nine commercially available surface coatings that can fine-tune the wettability and slipperiness at any given point in the device, thereby controlling how much droplets spread into pancakes or remain spherical, while also influencing their ease of movement down an incline.
By using these surface coatings in smart combinations, all necessary microfluidic elements required for a point-of-care test can be generated. For instance, if a certain location is extremely slippery and a droplet is positioned at a juncture where one side pulls liquid flat and the other pushes it into a ball, it acts like a pump and accelerates the droplet toward the former. The scientists devised numerous elements to manage the motion, interaction, timing, and sequence of multiple droplets within the device. Merging these elements, they fabricated a prototype test to measure human serum lactate dehydrogenase (LDH) levels. They carved channels into the testing platform to create designated routes for droplet passage, each coated with a substance preventing droplets from sticking along the way. Specific points were also pre-treated with dried reagents needed for the test, which are absorbed by droplets of simple buffer solution as they traverse the channels.
The maze-like test is then sealed with a lid equipped with holes for the sample and buffer solution to be dripped in. Once filled, the test is inserted into a box-shaped device with a handle that rotates the test by 90 degrees, allowing gravity to take over. The device also features a simple LED and light detector for swift and easy color-based test result assessment. This enables the scientists to label three different biomarkers with distinct colors for varying tests. In the LDH prototype test, the biomarker is marked with a blue molecule. A basic microcontroller measures the depth of the blue tint and the rate of color change, signifying the quantity and concentration of LDH in the sample, to yield results. This novel demonstration presents a new approach to the development of affordable, low-energy, point-of-care diagnostic devices. While the team intends to further refine their concept, they also hope it will spark interest and lead to the creation of similar tests by other researchers.
“Most microfluidic devices need more than just capillary forces to operate,” said Ashutosh Chilkoti, the Alan L. Kaganov Distinguished Professor of Biomedical Engineering at Duke. “This approach is much simpler and also allows very complex fluid paths to be designed and operated, which is not easy or cheap to do with microfluidics.”
Related Links:
Duke University
Latest Technology News
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Channels
Clinical Chemistry
view channel
Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
Endometriosis occurs when tissue similar to the uterine lining grows outside the womb, triggering inflammation, pain, and scarring. Diagnosis often relies on surgery and, in the UK, takes an average of... Read more
Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
Beckman Coulter Diagnostics has received CE Mark under IVDR for the Access p‑Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms... Read moreMolecular Diagnostics
view channel
Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations
Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more
Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with heterogeneous biology that complicates prognostication and treatment selection. Genetic testing clarifies many drivers, yet it... Read more
Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more
Extracellular Vesicle Marker Identifies Early Lung Adenocarcinoma and Predicts Recurrence
Lung cancer remains a leading cause of cancer death, and early-stage disease often produces few symptoms, complicating timely diagnosis and risk stratification. Conventional imaging and tissue biopsy have... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
CE-Marked Blood Assay Automates Tuberculosis Infection Testing
Tuberculosis continues to pose a major global health challenge, with an estimated 10.7 million people falling ill and 1.23 million deaths in 2024. Roughly one quarter of the world’s population is believed... Read more
Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
Genomic surveillance is essential for detecting viral variants before they spread widely, yet many public health systems face high costs, uneven capacity, and computational barriers. Existing analytic... Read more
Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
Acute infectious gastroenteritis remains a major cause of illness worldwide, especially in young children, older adults, and immunocompromised patients. Nonspecific symptoms such as diarrhea, vomiting,... Read more
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read morePathology
view channel
FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
Prostate cancer is the most common cancer among U.S. men, with more than 300,000 new cases and over 36,000 deaths each year. As targeted therapies emerge for biomarker-defined subgroups, laboratories need... Read more
New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
Recurrent breast cancer remains a persistent driver of morbidity and retreatment, and current risk stratification often depends on genomic assays that are costly and slow. Waiting weeks for results can... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more




.jpg)



